Slingshot members are tracking this event:

Seattle Genetics (SGEN) Granted Breakthrough Therapy Status by FDA for Adcetris in Patients with CD30-Expressing Mycosis Fungoides (MF) and Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL)

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 10, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Breakthrough Therapy Status, Fda, Adcetris, Cd30-expressing Mycosis Fungoides, Primary Cutaneous, Anaplastic Large Cell Lymphoma, Pcalcl, Mf